Legislator Giurisprudenza & Legislazione
IEHC 226 ECLI:IE:HC:2005:226 Generato dall'IA

High Court dismisses judicial review claim against Irish Medicines Board regarding organophosphate sheep dip safety. Applicant failed to prove manifest error or misuse of power.

Numero d'incarto IEHC 226
Autorità giudiziaria
Giurisdizione Irlanda (IE)
Data della decisione
Esito del giudizio Respinto (Dismissed)

Sintesi Legislator

Generato dall'IA

The High Court dismissed the applicant's judicial review application challenging the Irish Medicines Board's refusal to mandate new container standards for organophosphate sheep dips. The applicant argued that scientific reports indicated significant health risks and that the Board's reliance on existing safety data was flawed. The court held that the Board, as an expert body, was better positioned to evaluate complex scientific evidence than the judiciary and found no manifest error in its decision.

Regesto Legislator

Generato dall'IA

Judicial Review Act 1977, s. 1; Administrative Law: The court will not substitute its own judgment for that of an expert administrative body unless there is a manifest error of fact or an abuse of power.

Parole chiave

Generato dall'IA
judicial review manifest error expert body administrative discretion scientific evidence safety standards organophosphate sostanza pericolosa

Disposizioni normative citate

Generato dall'IA

Giurisprudenza citata

Generato dall'IA
Upjohn Limited v Licensing Authority (1999) 1 WLR 927
European Court of Justice in Upjohn Limited v Licensing Authority (1999) 1 WLR 927 and again in Matra S.A.
Matra S.A. v Commissioner of the European Communities (1993) ECR 1-3203
R v Licensing Authority Ex Parte Novartis Pharmaceuticals U.K. Limited
R v Medicines Control Agency Ex Parte Pharma Nord (UK) 1998 CMLR 109
Again in R v Medicines Control Agency Ex Parte Pharma Nord (UK) 1998 CMLR 109 at 121 Lord Woolf M.R.
2002 3 I.R. 148
County Council 2002 3 I.R. 148 as imposing upon the Court a duty to examine the accuracy of the findings of fact and law made by
Generato dall'IA

Ti chiedi come si applica questa sentenza alla tua fattispecie?

Analizza questa decisione insieme alla legislazione federale e cantonale, ai commentari e alla giurisprudenza successiva in Legislator AI.

Apri in Legislator →

Testo completo

2005 IEHC 226

THE HIGH COURT

2003 NO. 32 J.R.

HYGEIA CHEMICALS LIMITED

APPLICANT

AND

IRISH MEDICINES BOARD

RESPONDENT

Judgment of Finnegan P. delivered on the 4th day of May 2005

Facts

1. The Applicant is the producer of chemical products. In respect of two sheep dip products Hygeia Winter Dip and Hygeia Summer Dip

it holds Veterinary Product Authorisations granted for a period of five years from 1st October 1999 the Schedule to the Authorisations

having been varied on the 14th March 2001. The products are liquid organophosphate – based (hereafter OP) sheep dips. The

products contain 10% diazinon and are sold in plastic containers. To use the products the container is unscrewed and the product

poured into the sheep dip bath.

2. For some time there has been a concern that exposure to OP can result in neurological, psychological and psychiatric health

effects in humans. It is fair to say that the reports referred to in the course of this hearing are not fully conclusive as to the effects

of OP. However the Report of the Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment of November

1999 (“The COT Report”) justifies the concern in relation to acute poisoning and to a much lesser extent in relation to prolonged low

level exposure.

3. The Respondent (hereafter “IMB”) requested the Liaison Committee on Organophosphate Veterinary Concentrates to the Veterinary

Advisory Committee of the Irish Medicines Board to review the COT Report and other relevant Reports and scientific articles in relation

to OP concentrated solutions intended for veterinary use, to evaluate what changes if any were necessary to OP concentrates

intended for veterinary use, their containers, labelling and health and safety literature based on the scientific findings and the control

mechanisms for the supply of OP concentrated solutions intended for veterinary use. The Liaison Committee reported on the 21st

March 2000 and dealt with containers for OP product as follows –

“The Committee noted that current containers meet the current requirements under the Carriage of Dangerous Goods

by Road (Regulations) 1999 as drafted for transport of dangerous liquids. The Committee noted that considerable

variation existed in the type and size of containers marketed in Ireland. However no uniform standard for design

specifications of OP concentrate containers for veterinary use appear to be available. The reported practice among

some farmers to transfer concentrate to other smaller receptacles, thereby increasing the risk of exposure, appears to

have diminished through the provision of small volume containers. The Committee felt that more specialised expertise

was necessary to define any new standard for these containers. These specifications would in any event take time to

elaborate and products would have to demonstrate stability in any new container.

4. The following attributes would be desirable for such containers –

Durable to survive handling, storage and transport from the manufacturer through to farmer.

Capable of being opened while wearing the recommended gloves.

Where a handle is provided it should be offset from the spout, to minimise operator contact. It was suggested

that a handle would be necessary for handling products greater than one litre.

Have a wide spout opening to avoid glugging.

Have a spout which would extend and not allow the fluid to dribble and to pool on the top surface.

A closed system of delivery was considered by the Committee as an alternative, but it was acknowledged that there

were many practical problems associated with this option. It was noted that there is no generically available system.

Many of the simpler closed systems would lead to exposure to the operator at the point of setting up or dismantling or

would not give the necessary control for the performance needed or would have a potential for misuse.

Attempts to improve existing containers through the provision of a screw top tap for insertion on to the product

containers had proved unsuccessful due to cross threading and tap leakage. Other possibilities for ensuring the integrity

of the concentrate such as the use of alginates were rejected on the basis of design failures and the need to have a

product capable of use at different concentrations to fulfil the requirements for differing initial and replenishment loads

which are needed to meet the so called stripping characteristics of the product”.

4. The Committee among its recommendations made the following –

“That the containers in which OP concentrates are supplied for veterinary use be kept under review by the Irish

Medicines Board in the light of national and international developments and that all authorised products should comply

with any new standards”.

5. The Advisory Committee on Veterinary Medicine of the I.M.B. endorsed the Report of the Liaison Committee on the 15th March

2001. On the 19th November 2001 the I.M.B. wrote to the Applicant and having referred to the recommendation of the Liaison

Committee said –

“The I.M.B. is aware that new standards in delivery systems have been developed or are currently under development

by a number of relevant companies. This issue was discussed at a recent meeting of the Veterinary Advisory Committee

who concluded that, for all relevant products on the Irish market, new closed delivery systems or similar, aimed at

reducing operator exposure to the concentrate must be in place before 31st October 2002 and any product not in

compliance with the new standard at that date should be recalled from the market”.

6. At this time two suppliers to the Irish market had introduced closed delivery –

Coopers Ectoforce introduced a system consisting of an outer foil bag containing an inner water soluble sachet containing

the OP and Osmond Goldfleece a pumped delivery system. Each of these products contain 60% diazinon whereas the

Applicant’s product contains 10% diazinon. Further in 1995 the Applicant in order to avoid risks where the container was

of tin plate introduced its plastic container and which while not a closed system as recommended by the Liaison

Committee the Applicant contends that it meets all the criteria for containers set out in the Liaison Committee’s Report.

6. The Applicant responded to the I.M.B.’s letter of the 19th November 2001 by letter dated 16th July 2002 with which they enclosed

a Report which had been commissioned from Willis Corroon Hinton (Ireland) Limited (hereinafter “Willis Report”) The Willis Report

contained a hazard identification and risk assessment of all three products on the Irish market – that of the Applicant, Coopers

Ectoforce and Osmond Goldfleece. It dealt with the Applicant’s container in the following terms –

“Hygeia dip is dispensed from a plastic container with an open spout. This presents the risk of splashing and dripping of

product from the rim of the spout after pouring and when the cap is replaced. However, this risk is minimised through

the use of an offset handle (at the opposite side to the spout) and the wide spout which reduces the likelihood of

glugging.

An important point to note is that the Hygeia dip has a concentration of only 10% compared to 60% for the other two

products. This means that if contact does occur, the risk of adverse health effects will be significantly lower. Indeed it is

arguable that the Hygeia product should not be classified as a “concentrate””.

7. It identified the risk associated with Coopers Ectoforce as a risk of puncture and the risk associated with Osmond Goldfleece that

the complex nature of its delivery system could present problems in the field. The Report concluded that it would appear that only the

Hygeia product clearly meets the I.M.B. requirements, that is the recommendations of the Liaison Committee.

8. The substantive response from the I.M.B. was by letter dated 19th August 2002 in the following terms-

“At a meeting of the Advisory Committee for Veterinary Medicines in October 2001 the issue of new standards in delivery

systems for OP sheep dip concentrates was discussed. The Committee decided that “new closed delivery systems, or

similar, aimed at reducing operator exposure to the concentrate must be in place before 31st October 2002 and any

product not in compliance with the new standard at that date should be recalled from the market.” This decision was

communicated to you in a letter dated 19th November 2001.

As a follow-up to that letter, and notwithstanding the fact that an appeal to the decision detailed above will be

considered at the September meeting of the A.C.V.M., I am writing to ascertain the stocks of summer dip and winter dip

remaining on the market at this point in time. Further, in the event that your appeal to the A.C.V.M. is not successful,

you are requested to confirm that no product in the “open” system will be introduced to the Irish marketplace after the

October 31st deadline. As indicated previously, any product and delivery systems not acceptable to the I.M.B. and

remaining in the marketplace after October 31st should be recalled”.

9. The I.M.B. sent a second letter to the Applicant dated 19th August 2002 dealing with the appeal and as there is an issue in these

proceedings in relation to the appeal and the appeal procedures I propose dealing with that correspondence separately. The Advisory

Committee met to consider the appeal against its decision communicated in the letter of the 19th November 2001 on the 18th

December 2002 and its decision on the appeal was communicated by letter dated 19th December 2002 and dealt with the outcome of

the appeal in the following terms –

“Following the discussion the A.C.V.M. is of the unanimous opinion that organophosphate concentrates supplied in open

containers that require the user to pour the concentrate into the sheep bath carry an unacceptable risk of user

exposure to the concentrate. For this reason the A.C.V.M. decided that Hygeia’s winter dip and summer dip as currently

presented to the end user carry an unacceptable risk of human exposure to the organophosphate concentrate which

arises during their use for dipping sheep.

Therefore the A.C.V.M. have moved to suspend the marketing authorisations for both products in accordance with

Regulation 19 of the Animal Remedies Regulations 1996 and Article 83 of Directive 2001/82/EC. Consequently, you are

directed not to continue to supply winter dip and summer dip to the market and that any product on the market

currently should be recalled from retailers before January 31st 2003. A draft recall notice must be provided too and

approved by the I.M.B. Inspectorate prior to issue by you. In addition, farmers should be advised by an appropriate

notification from your company to return any unopened products to the source of purchase for uplifting by your

company. This notification should also be submitted to the I.M.B. for review and approval prior to issue. You are

requested to contact Mr. John Lynch or Ms Muireann Lydon, I.M.B. Inspectorate, in respect to the conduct of the recall.

I should point out that the suspensions will be lifted should applications for an appropriate delivery system be submitted

and authorised by the I.M.B”.

10. The I.M.B. met on the 26th February 2003 to consider the suspension of the product authorisations for the Applicants’ products

and decided that the product authorisation for the same should be suspended. It was decided that a recall of the products should be

commenced so that all products be removed from the market by the 9th April 2003.

The Proceedings

11. On the 22nd January 2003 (that is prior to the decision of the I.M.B.) the Applicants applied for and were granted leave to apply

for certain reliefs by way of judicial review. The Applicants also sought interlocutory relief in the nature of a stay on the decision of

the Respondent and this was granted on the 21st March 2003. With leave of the Court the Applicants delivered an amended

Statement Required to Ground Application for Judicial Review on the 17th April 2003 and an amended Statement of Opposition was

delivered to the same.

The Issues

12. At my request the parties agreed the issues for determination by the court in the following terms –

(1) Whether the internal procedures adopted by the Respondent failed to comply with the principles of natural and

constitutional justice and basic fairness of procedures and (sic) any of the grounds identified in paragraph 47 of the

statement of grounds; or were in breach of the principles stated in paragraph 49 (being the principle of proportionality and

respect of fundamental rights including rights of property, the principle of legal certainty and protection of legitimate

expectation and the principle of equality).

(2) Whether the decision of the Respondent is ultra vires on the grounds set out in paragraphs 37 and 38 of the amended

statement of grounds.

(3) Whether the decision of the Respondent was arrived at in breach of the principle of proportionality in circumstances

where there were no adverse reactions or adverse human reactions to the Applicants’ products.

(4) Whether the Respondent impermissibly took into account the economic implications for companies which are the

competitors of the Applicant.

(5) Whether the decisions of the Respondent were vitiated by objective bias by (a) predetermination or (b) the

participation of Mr. P.J. O’Connor, Chairman of the Advisory Committee for Veterinary Medicines in the decision of the

Board on the 26th February 2003.

(6) Whether the decision of the Respondent is vitiated by subjective bias (paragraph 44 of the amended statement of

grounds).

(7) Whether the decision of the Respondent is vitiated by manifest error or misuse of power as identified in paragraph 51

of the amended statement of grounds; and whether the decision of the Respondent is vitiated by a distortion or manifest

error of assessment of facts or misuse of power or a clear breach of the bounds of its discretion as a consequence of (i)

the non-disclosure of the rapporteur’s Report; or (ii) omission to refer to “or similar aimed at reducing operator exposure

to the concentrate”.

(8) Whether the decision of the Respondent on the 26th February 2003 cures any defect in the procedures to that date

or whether they are fatally tainted.

(9) Whether the Applicant is estopped from challenging the procedures of the oral hearing.

(10) Whether the Applicant is estopped from raising the issue of subjective bias of Dr. Beechner in circumstances where

the Applicant did not object to Dr. Beechner’s presence at the oral hearing before the Advisory Committee for Veterinary

Medicine.

(11) In the event that the Applicant is successful on all or some of the above issues whether there is any liability in

damages and if so how much.

(It is understood that the above issues relate to the decision of the Advisory Committee for Veterinary Medicines made on

the 18th December 2002 and the decision of the Irish Medicines Board made on the 26th February 2003 as appropriate).

The Regulatory Framework

13. The I.M.B. was established by the Irish Medicines Board Act 1995 (“The Act”). The functions of the I.M.B. are set out in section 4

of the Act and include the licensing of the manufacture, preparation, importation, distribution and sale of medicinal products, the

exercise of the powers conferred on the competent authority by Council Directive No. 65/65 EEC and any Regulations under the

Health Act 1947 giving effect to that Directive, the exercise of the powers conferred on the Supervisory Authority by Council

Regulation (EEC) No. 2309/93 and Council Directive No. 81/851/EEC. Council Directive No. 81/851/EEC was repealed and its provisions

re-enacted by Council Directive 2001/82/EC which in effect codified the law in relation to veterinary medicinal products. The Act in

section 9 provides for the establishment by the Minister of the Advisory Committee on Veterinary Medicines “to assist and advise the

Board in relation to any matters pertaining to the safety, quality or efficacy of medicinal products for animal use as are referred to it

by the Board and to perform the functions assigned to it by sub-section (8)”. The members of the Committee are appointed by the

Minister for Health with the consent of the Minister for Agriculture, Food and Forestry and the Chairperson of the Committee is

appointed by the Minister. Sub-section (5) provides that the Committee shall regulate “by standing orders or otherwise” the

procedure and business of the Committee. Sub-section (8) provides as follows –

“The Board shall not refuse to grant a licence in respect of a medicinal product on any ground relating to the safety,

quality or efficacy of the medicinal product unless it has requested the advice of the appropriate committee in relation

thereto and considered such advice”.

14. Council Directive 2001/82/EC Article 83 provides as follows –

“1. The competent authorities of the member states shall suspend or withdraw marketing authorisation when it is clear

that

(a) The veterinary medicinal product proves to be harmful under the conditions of use stated at the time of

application for authorisation or subsequently”.

15. Article 94 of the Council Directive provides as follows –

Any decision referred to in this Directive, taken by the competent authorities of the member states, may only be taken

on the grounds set out in this Directive and shall state in detail the reasons on which it is based.

Such a decision shall be notified to the party concerned who shall at the same time be informed of the remedies

available to him under current legislation and the time allowed for seeking such remedies.

16. The relevant domestic Regulations are the Animal Remedies Regulations 1996. The Regulations in Regulation 5 provide that the

I.M.B. shall be the Competent Authority in the State for the purpose of the Council Directive: Council Directive is defined by listing the

relevant Directives then in existence but also “any future Directive of the Council, or, as the case may be, the Commission, made

after the making of these Regulations which amends, extends or replaces the said Council Directive 81/851/EEC”.

17. The I.M.B. accordingly is the Competent Authority for the purposes of Council Directive 2001/82/EC.

18. The Regulations in Regulation 19 provide as follows –

“19. The Competent Authority shall suspend or revoke a veterinary product authorisation where in the opinion of the

Competent Authority –

(i) The animal remedy proves to be harmful under the conditions of use stated at the time of application for

authorisation or subsequently”.

19. I propose dealing with the objections of the Respondent on the grounds of estoppel at Issues 9 and 10 first.

9. Whether the Applicant is Estopped from Challenging the Procedures of the Oral Hearing.

20. The Respondent treated a letter to it from the Applicant dated 16th July 2002 as an appeal against the decision of the Advisory

Committee for Veterinary Medicines (“A.C.V.M.”) communicated by the letter dated 19th November 2001. By letter dated 19th August

2002 the Respondent informed the Applicant that the A.C.V.M. would consider the appeal documentation which had been provided by

the Applicant. By letter dated 6th September 2002 the Applicant requested that it be given an opportunity to attend before the

A.C.V.M. The Respondent wrote to the Applicant on the 19th September 2002 following a meeting of the A.C.V.M. on the 16th

September 2002 in the following terms –

“The A.C.V.M. reviewed the totality of the documentation provided, including recent correspondence between Hygeia

and the I.M.B. since we received your submission. The A.C.V.M. deferred a decision on the matter pending further

deliberation. They requested the Veterinary Secretariat to prepare an assessment report of the Hygeia submission for

consideration by it at its next meeting on November 20th 2002. If necessary following their consideration of the matter

the A.C.V.M. will issue an updated position paper on the matter. In the interim the A.C.V.M. have deferred a recall of the

Hygeia products. The A.C.V.M. does not consider that it would be useful at this juncture to have a hearing with you in

person as the Veterinary Secretariat have yet to report. However, if the Committee is minded to confirm its previous

position that closed delivery systems for OP concentrates are necessary, you will be given the opportunity to appeal”.

21. There followed an exchange of correspondence in which the Respondent requested further information which was provided by the

Applicant. By letter dated 21st November 2002 the Advisory Committee acceded to the request to be allowed attend before it on the

appeal and dealt with the form which the appeal would take in the following terms –

“As requested in your letter of September 6th you are invited to attend before the A.C.V.M. to appeal this decision. You

are requested to present yourself at the I.M.B. at 3.30 p.m. on December 18th 2002 for the appeal which is expected to

last for 20/30 minutes. You are also requested to provide copies of any written documents/overheads you wish to

present to the I.M.B. in advance for consideration by the I.C.V.M. These documents which should be marked for my

attention should be submitted no later than Monday 9th December to allow for copying, dispatch and consideration by

the members of the Committee. Please indicate whether you have any requirements for an overhead or computer

projector at that time. You are also requested to advise me of the names of members of your delegation which should

not exceed four persons. The appeal should involve a technical, scientific presentation/discussion only and will be based

on the safety of your products for human health. Following your presentation, it is expected that members of the

A.C.V.M. may ask questions of clarification on the information presented”.

22. The Applicant responded to this letter on the 26th November 2002 raising three matters –

(i) The inadequacy of the time allowed to prepare for the appeal.

(ii) Requesting copies of studies referred to in a Report of the Advisory Committee for Veterinary Medicines of 20th

November 2002 sent to the Applicant with the letter of 21st November 2002 (this document is referred to hereafter as

the Risk Assessment).

(iii) Requesting a copy of a Risk Assessment carried out in relation to all three products on the market.

23. In its reply of the 27th November 2002 the Respondent refused the request to defer the appeal and declined to furnish studies

related to competitor products for reasons of confidentiality and on the grounds that other products are not relevant to the risk

evaluation of the Applicant’s product. Copies of the studies requested were not furnished with that letter but were subsequently

furnished in advance of the hearing of the appeal. The letter of the 27th November 2002 set out in more detail the appeal procedure

in the following terms-

“(1) Submission of copies of any written documents/overheads you wish to present to the I.M.B. for consideration by

the A.C.V.M. These documents, which should be marked for my attention should be submitted no later than Monday

December 9th 2002 to allow for copying, dispatch and consideration by the Members of the A.C.V.M. Note that the

appeal documentation is intended to clarify issues already identified and not to present the results of any new studies.

(2) Notification to the I.M.B. of the names and professional description of members of your delegation attending the

appeal (up to a maximum of four persons) in advance of the appeal which will take place at approximately 3.30 p.m. on

Wednesday December 18th 2002.

(3) The appeal should involve a technical, scientific presentation/discussion only before the A.C.V.M. and will be based on

the safety of your products for human health. The appeal is expected to last for 20/30 minutes. The appeal should focus

on the risk of the Hygeia products for human health; matters relating to commercial considerations or to products

marketed by other companies are outside the scope of the appeal.

(4) Following your presentation it is expected that members of the A.C.V.M. may ask questions of clarification on the

information presented.

(5) Following your appeal to the A.C.V.M. you will be invited to withdraw from the meeting. The meeting will close

regarding your input and the A.C.V.M. will consider the matter.

24. Following this the solicitors for the Applicant became involved and wrote to the Respondent on the 10th December 2002 raising a

number of matters in relation to the procedures on the appeal. They sought a copy of the Rules for appeals, a copy of the Risk

Assessment, a copy of a Study on the Solubility of Sachets. Objection was made to the circumstance that the appeal would be to

the same Advisory Committee as had made the original decision. Objection was taken to the time limit of 20/30 minutes. Again

objection was taken to the scope of the appeal as set out at (3) in the extract from the Respondent’s letter of the 27th November

2002 set out above. The letter went on to state that it was under protest that the Applicant will participate in the appeals procedure

and that it would do so without prejudice to all other avenues and remedies available to it. In response to that letter the Respondent.

by letter dated 13th December 2002 set out in considerably more detail the manner in which the appeal would proceed. It also set out

the sources relied upon for the preparation of the Risk Assessment. Access to any study on the solubility of sachets was denied. In

relation to the constitution of the A.C.V.M. it pointed out that the members of that Committee are appointed by the Minister and that

the Act does not provide for a differently constituted Committee to hear appeals. It pointed out that a member of the Committee had

been appointed to act as Rapporteur and not the member of the I.M.B. staff who prepared the Risk Assessment. With regard to the

limitations on the appeal it pointed out that the procedure adopted is in accordance with the practice of international regulatory

bodies such as the European Medicines Evaluation Agency which restrict oral presentations. The Applicant’s solicitors responded by

letter dated 17th December 2002 again seeking a copy of formally adopted rules or regulations for appeals, requesting a copy of the

signed Risk Assessment and the Study of Solubility of Sachets. The objection to the appeal being considered by the same Committee

as made the decision was repeated. It objected to the restriction on the introduction of further independent reports and to the limit

for an oral presentation of 20/30 minutes. It was indicated that the Applicant intended to rely on a Report of Professor Hynes and this

was in fact considered by the Committee. Finally it was indicated that the submission of the Applicant to the appeal process was not

to be taken as an acceptance on their part of the lawfulness or otherwise of the matters complained of in the correspondence.

25. In determining whether the objection on the grounds of estoppel is well founded I think it is appropriate to have regard to the

time constraints with which the Applicant was faced. It is also appropriate to have regard to the circumstance that the procedures to

be adopted by the A.C.V.M. were stated originally in the letter of 21st November 2002 from the Respondent and expanded upon and

clarified in the further letters dated 27th November 2002 and 13th December 2002. The Applicant’s position in relation to the

procedures was expressly reserved in their solicitor’s letters of the 10th December 2002 and 17th December 2002. Thus there was no

acquiescence on the part of the Applicant in the stipulated procedures. The circumstances here accordingly differ from those in

Corrigan v Irish Land Commission (1977) I.R. 317 relied upon by the Respondent where the Plaintiff sought to impugn a decision of

the Defendant on the ground of bias in circumstances where two of the lay commissioners who heard the case had previously signed

a certificate for the compulsory acquisition of the Plaintiff’s lands. The Applicant in that case did not object to the participation of the

lay commissioners during the course of the hearing. The term “estoppel” is used in various senses in the law but in each case it seems

to me to have as an ingredient the adoption by one party of a position upon which the other relies. In the circumstances of this case

the Applicant has never adopted the position and did not lead the Respondent to believe it had adopted a position that it was

satisfied with the procedures: rather it had made its objections known and indicated that it intended to reserve its position in relation

to the same. I am satisfied accordingly that the Applicant is not estopped.

10. Whether the Applicant is Estopped from Raising the Issue of Subjective Bias of Dr. Beechner in circumstances where

the Applicant did not object to Dr. Beechner’s presence at the oral hearing before the Advisory Committee for Veterinary

Medicine.

26. Dr. Beechner acted as Secretary to the Liaison Committee on Organophosphate Veterinary Concentrates whose Report of the

31st March 2000 recommended that the containers in which OP Concentrates are supplied for veterinary use be kept under review by

the Respondent. He is also the Veterinary Director of the Respondent and correspondence from the Respondent to the Applicant was

under his hand. The Applicant contends that Dr. Beechner sat on the A.C.V.M. when it made its decision of October 2001 although

not a member: further he sat on the A.C.V.M. which heard the appeal. He remained with the A.C.V.M. after the hearing of the appeal

and participated in its deliberations. He communicated the decision of the A.C.V.M. on the appeal. He prepared a memorandum which

was before the Respondent when it made its final decision. He was the author of the Report of the National Drugs Advisory Board

1995 on OP Sheep Dips.

27. I have carefully considered the Affidavit of Dr. Beechner in response to the allegations of his participation in the deliberations of

the A.C.V.M. at the time of its original decision and on the appeal hearing and the deliberations of the A.C.V.M. following that hearing.

I have carefully considered the evidence of Dr. Beechner on cross examination. On the evidence before me I am satisfied that Dr.

Beechner was not involved in the deliberations of the A.C.V.M. either on the making of the original decision or on the appeal hearing in

the sense suggested by the Applicant. Insofar as the latter is concerned the Applicant was present and made no objection: in these

circumstances on the authority of Corrigan v Irish Land Commission (1977) I.R. 317 I am satisfied that the Applicant is in any event

estopped from raising the objection at this stage having failed to do so in the course of the appeal. However there was no possibility

for the Applicant to object to any involvement if such there had been by Dr. Beechner in the deliberations of the A.C.V.M. following

the appeal hearing: however I am satisfied on the Affidavit evidence before me that Dr. Beechner did not participate in the

deliberations. In summary the objection on the basis of estoppel succeeds only insofar as it relates to proceedings on the appeal

hearing. As I reviewed the evidence in relation to Dr. Beechner’s involvement throughout the entire process in connection with this

issue I propose to deal next with Issue 6 and in conjunction with the same the issue raised at 5(a) and which also relates to Dr.

Beechner’s involvement.

Issue (6)

Where the Decision of the Respondent is Vitiated by Subjective Bias (paragraph 44 of the amended Statement of Grounds)

5(a) Whether the Decisions of the Respondent were Vitiated by Objective Bias by predetermination

28. Paragraph 44 of the Amended Statement of Grounds reads as follows –

“Before the hearing of the appeal Mr. Declan O’Brien, Director of Animal and Plant Health Association (A.P.H.A.) was told

by Dr. Beechner on or about the 20th November 2002 in a conversation that it did not matter what Hygeia presented at

its appeal as the decision had already been made to withdraw its sheep dips. The Respondent’s decision communicated in

the letter of the 19th December 2002 is thus vitiated by prejudgment and bias. The Animal Plant Health Association

represents the views of the industry in respect of its member plant pharmaceutical companies.”

29. Declan O’Brien swore an Affidavit on the 16th January 2003 in which he deposed as follows –

“On the 20th day of November 2002 I had a conversation with Dr. Gabriel Beechner, Veterinary Director, Irish Medicines

Board in relation to various matters. In the course of our conversation we spoke about the current position with Hygeia’s

sheep dip products and the forthcoming appeal on the 18th December 2002. Dr. Beechner indicated that it did not matter

what was said at the forthcoming appeal as the decision had been made to remove the products from the market. I

understood this to mean that the outcome of the forthcoming appeal had already been determined.”

30. Mr. O’Brien was cross examined on his Affidavit. He could not remember the words used by Dr. Beechner but that the effect of the

words was that the products would be removed regardless of what was said at the appeal. He had read Dr. Beechner’s Affidavit in

response to his Affidavit. The conversation was in relation to sheep dip products generally. He was aware of the Applicant’s appeal

and when it was due to be heard. He was aware of the views of the I.M.B. in relation to closed delivery systems and he was aware in

general terms that the A.C.V.M. wanted the product to be marketed with closed delivery systems. He was unable to recall precisely

the context in which he alleged Dr. Beechner made the comments in question. He could not recall whether it was in a response to a

question posed by him but it may have been. He was unable to recall with any precision anything else that was discussed. He had

told Mr. McCartan, the Managing Director of the Applicant, of the conversation on the 4th December 2002. When he told Mr.Cartan of

the conversation he could not remember whether he had phoned Mr. McCartan or vice versa but it was more likely that Mr. McCartan

had phoned him. In a subsequent telephone conversation with Dr. Beechner he may have said that what he told Mr. McCartan that

Dr. Beechner had said was that it was unlikely that the Applicant would be successful on the appeal. In the course of that

conversation Dr. Beechner had disagreed with the witness’s account of the conversation. He did not agree that Dr. Beechner had

merely explained to him his understanding of the concerns of the A.C.V.M. with sheep dip products. He denied that he told Dr.

Beechner that at the time he swore his Affidavit he could not recall what he had told Mr. McCartan but had relied on Mr. McCartan’s

account of what he had told him. He had prepared a statement before the Affidavit was sworn and when presented with this he had

corrected it: on further questioning he said the statement may not have been supplied in writing but may have been given in the

course of a telephone conversation with the Applicant’s Solicitors which was then put in writing and which he had corrected. There

was a reference to precise words in the Draft Affidavit which he did not put into the Affidavit as sworn. The initial draft was in effect

putting words into his mouth. A contemporaneous note of the witness’s conversation with Dr. Beechner made by Dr. Beechner was

put to the witness. He disagreed with the note in that it recorded him as saying that he had telephoned Mr. McCartan on the morning

following his discussion with Dr. Beechner that is on the 21st November 2002. He disagreed with the note in that it recorded him as

having told Mr. McCartan that it was unlikely that the company would be successful in its appeal. The note read as follows –

“He stated that he was in a difficult position because if he did not sign the Affidavit he would be liable to court action

from the company involved”.

31. The witness remembered saying words to that effect: he believed if he did not swear the Affidavit he would be subpoenaed. The

note contained the following –

“I told him that at the appeal itself the Chairman at the outset following his welcoming address to the company he had

stated that the A.C.V.M. were open minded on the outcome of the appeal and would reach a conclusion on the matter

following the appeal. I stated that that statement had been included in the stenographers note of the meeting”.

32. The witness accepted that could have been said by Dr. Beechner. He was unable to say that other matters recorded in the note

were not dealt with in the conversation. The witness agreed that he had not sworn an Affidavit in response to Dr. Beechner’s

Affidavit: he had only seen that Affidavit some ten days previously.

33. A letter dated 21st November 2002 was put to the witness which letter notified the Applicant of the date of the appeal: this was

the day after the conversation which he had had with Dr. Beechner: it was suggested to him that he could not possibly have known

that the appeal date had been fixed for the 18th December at the time of the conversation. The witness was adamant however that

he knew that there was an appeal pending although it may have been the case that he did not know the date fixed. As of that date

however the decision of the A.C.V.M. had not been communicated to the Applicant the decision having only been made on the day of

his meeting with Dr. Beechner. He believed his conversation with Dr. Beechner on the evening in question lasted between fifteen and

thirty minutes. The witness could not recollect a discussion on another matter which took place during the conversation and referred

to by Dr. Beechner in his Affidavit.

34. Having considered the evidence of the witness on Affidavit and in cross examination and also that of Dr. Beechner on Affidavit

and in cross examination my conclusion is as follows. I am satisfied that a discussion took place concerning the Applicant’s position.

Both Mr. O’Brien and Dr. Beechner were aware of the attitude of the A.C.V.M. Dr. Beechner was aware of the decision of the A.C.V.M.

reached on that day. I think it likely that Mr. O’Brien anticipated a decision of the A.C.V.M. unfavourable to the Applicant and

anticipated an appeal. I do not accept that Dr. Beechner said that an appeal would be unsuccessful: at most he may have expressed

his opinion that the appeal was unlikely to succeed. In these circumstances I am not satisfied that the Applicant has established any

element of prejudgment in relation to the appeal process.

Issue (1)

Whether the internal procedures are adopted by the respondent failed to comply with the principles of natural and

constitutional justice and basic fairness of procedures and any of the grounds identified in paragraph 47 of the Statement

of Grounds; or were in breach of the principles stated in paragraph 49 (being the principle of proportionality and respect of

fundamental rights including rights of property, the principle of legal certainty and protection of legitimate expectation and

the principle of equality).

35. Paragraph 47 of the Amended Statement of Grounds criticises the Respondent’s procedures in the following terms –

(i) There are no formal written procedures (whether by way of regulations, standing orders or otherwise) describing the

manner in which the Respondent’s Advisory Committee for Veterinary Medicines conducts appeals.

(ii) The review is considered initially by the Respondent’s Advisory Committee for Veterinary Medicines.

(iii) The appeal from the initial decision of the Respondent (through its Advisory Committee for Veterinary Medicines) is to

the said Advisory Committee for Veterinary Medicines.

(iv) The appellate procedure constitutes the Respondent (through its Advisory Committee for Veterinary Medicines) a

judge in its own cause and fails to respect the nemo iudex in causa sua principle.

(v) The entire procedure is opaque and appears to be conducted on an ad hoc basis according to whatever rules the

Respondent’s Veterinary Director lays down.

(vi) The absence of published and transparent procedures for applications and appeals before the Advisory Committee for

Veterinary Medicines of the Respondent makes the Respondent a judge in its own cause in which it also acts as the

presenting or prosecuting authority and participates in the deliberations of the said Advisory Committee for Veterinary

Medicines.

(vii) Requiring the Applicant in its written documents and appeal to produce independent evidence and experts in its

appeal while allowing the Respondent to rely upon limited written reports or extracts from scientific literature with no

opportunity to verify or question assertions made.

(viii) Adopting a procedure for appeals before the Advisory Committee for Veterinary Medicines which encompassed pre

judgments on the part of the Respondent.

(ix) Relying on an anonymous unsigned and unpaginated risk assessment.

(x) Acting ultra vires its powers as outlined in paragraphs 37 and 38 above.

36. (i), (ii) (other than in relation to the allegation that the procedures are opaque) and (iii) above are factually correct. Insofar as

procedures are concerned the Irish Medicines Board Act 1995 section 8(8) provides as follows –

“Subject to the provisions of this Act, the Board shall regulate, by standing orders or otherwise, the procedure and

business of the Board”.

37. Accordingly it is open to the Board to adopt such procedures as it thinks fit by standing orders or otherwise. There are no

standing orders but this does not represent a defect provided the procedures actually adopted are fair and notified. The procedures

of the A.C.V.M. in its initial consideration were I am satisfied sufficient and appropriate to the administrative determination involved:

in any event it is quite clear that that determination was not final but was subject to what throughout the proceedings was referred

to as an appeal procedure. In fact the position was that a preliminary view was formed by the A.C.V.M. and the Applicant was then

allowed to make its case before that view was incorporated into a decision in relation to the advice which would be given to the

I.M.B. For the appeal procedure I am satisfied that the procedures outlined in correspondence prior to the hearing were appropriate

and sufficient. The Applicant however raises a number of specific complaints concerning the preliminary decision and the decision on

appeal (as it has been categorised). The Applicant sought but was denied access to the result of tests on the solubility of sachets as

a method of delivery utilised by a rival company. I am satisfied that the Applicant was not entitled to this information. The

Respondent was concerned with the Applicant’s product and not with the rival product. It is complained that the Respondent

arrogated to A.C.V.M. competence to make the decision: on the evidence this was not the case. The decision was made by the Irish

Medicines Board whose function this is under the Animal Remedies Regulations 1996 Regulation 19. Further the Irish Medicines Board

Act 1995 section 9(8) recognises a role for the A.C.V.M. in relation to the grant of a licence. However the role of the A.C.V.M. is

wider than this as section 9(2) provides for the establishment of an A.C.V.M. to advise the Board in relation to matters pertaining to

the safety, quality and efficiency of medicinal products for animal use as are referred to it by the Board. I am satisfied that it was

appropriate for the Board to avail of the expertise of the A.C.V.M in this instance. The A.C.V.M. I am satisfied made no decision either

at the preliminary stage or at the appeal stage both of which stages were designed to enable the A.C.V.M. to form an opinion and

advise the Board. There is a complaint of “a rush to judgment”. The concerns in relation to OP products and their manner of

application were long known to the Applicant as they were to other manufacturers and suppliers of products containing OP. This was

particularly the case following on from the COT Report, the Report of the Liaison Committee of 21st March 2000 and the endorsement

of the same by the A.C.V.M. on the 15th March 2001. I am satisfied that the procedure adopted whereby a preliminary decision was

reached subject to the facility afforded to the Applicant to make representations prior to a final view being reached was sufficient

and appropriate in the circumstances of this case. Complaint is made of a risk assessment prepared by Dr. Beechner principally that it

was not disclosed that he was the author of the same. Had I been persuaded by the Applicant’s arguments that Dr. Beechner was

biased this would have been relevant but as I have not accepted that submission I do not accept that the omission to name him as

the author vitiates the proceedings of the A.C.V.M. or the Respondent.

38. The Applicant makes specific criticism of the role of rapporteur. In his evidence and on cross examination Dr. Beechner described

this procedure as having been adopted from procedures at EU level. Mr. Breathnach and expert toxicologist on the A.C.V.M. was

appointed to act. His function was to overview the Risk Assessment Report prepared by Dr. Beechner. He was also to assess and filter

the documentation put before the A.C.V.M. at the appeal stage. He prepared a Report for the A.C.V.M. The Report in this case was

critical of some of the expert reports relied upon in the Risk Assessment and this was not disclosed to the Applicant. The procedure

adopted by the A.C.V.M. is that any matters in the rapporteur’s report favourable to the company whose product is being considered

are not put to the company but it is given an opportunity to deal with those matters in the report unfavourable to it. In the

circumstances of this case I am satisfied that the rapporteur is acting as a member of the A.C.V.M. for the benefit of the committee

in the manner outlined by Dr. Beechner but that as a member of the A.C.V.M. may express views on the matters before it.

Proceedings before the A.C.V.M. are not inter partes. He is not fulfilling the role of a legitimus contradictor to an applicant company.

As a member of the committee it is appropriate that he should raise questions of a company seeking to obtain or maintain an

authorisation. I would not think it appropriate that he should, as is suggested by the Applicant, ask questions of the A.C.V.M. The

position here is not as that in Frenchchurch Properties Limited v Wexford County Council 1991 ILRM 769 where there was a matter

exercising the mind of the Respondent’s official which the Applicant was not given the opportunity to deal. Here I am satisfied that

the Applicant was given an opportunity at the oral hearing to deal with all matters which were of concern to the A.C.V.M.

39. Next criticism is made that in its letter of the 19th November 2001 to the Applicant the Respondent wrote that what was required

before 31st October 2002 was a “new closed delivery system or similar” but throughout proceedings before the A.C.V.M. the

alternative of a “similar” system was not canvassed. It is clear from the evidence that the Applicant’s system is an open system and

not a closed system and it is not a system that could in any way be described as coming within the phrase “or similar”. I do not see

this submission as relevant.

40. Finally there is criticism of reliance by the A.C.V.M. on a test of the Applicant’s product carried out by Dr. Beechner which has

been described as the “toilet test” this being the manner in which Dr. Beechner tested the Applicant’s container. The test to me

appeared a sensible, practical examination: the Applicant for its part relied on “a desktop examination of the hazards associated with

the Applicant’s products” by which I understand that no practical tests whatsoever were carried out for the purposes of the same.

Where the Applicant itself did not consider it appropriate to carry out any practical tests and I see little merit in its complaint

concerning the test carried out by Dr. Beechner.

41. The requirements of natural justice vary with the nature of the enquiry concerned. In the present case I am satisfied that the

procedures adopted satisfy the requirements of natural justice. The Applicant was afforded the opportunity to make its case in the

procedure adopted. This was an administrative procedure and not in the nature of judicial proceedings inter partes.

42. In paragraph 49 of the Amended Statement of Grounds the Applicant calls in aid the principle of proportionality and respect for

fundamental rights, legal certainty, protection of legitimate expectations and the principle of equality. It is common case that there is

no instance of adverse human reaction to the Applicant’s product. However it is also abundantly clear that there are serious concerns

as to the effect on human health of OP products: see for example the COT Report. In addition to the principles urged by the Applicant

it is appropriate to have regard to the precautionary principle. I am satisfied having regard to the documented concerns in relation to

OP products the decision reached by the Board to withdraw the authorisation was proportionate. The Applicant had a legitimate

expectation of fair procedures but these I am satisfied were accorded to it. Other than to raise in the pleadings the principle of

equality this was not elaborated upon.

43. The Applicant complains that the A.C.V.M. by letter dated 19th December 2002 required withdrawal of the Applicant’s product by

the 31st January 2003 while the next meeting of the Respondent, being the earliest at which a decision could be made, was

scheduled for the 29th January 2003: however the Applicant’s product was not in fact withdrawn injunctive relief having been

obtained. The course of conduct may reflect confidence that the advice of the A.C.V.M. would be followed by the Respondent but it

does not convince me that there was prejudgment as the decision made was on the evidence not that of the A.C.V.M. but of the

Respondent. The A.C.V.M. being the expert body to advise the Respondent clearly expected its advice to be heeded and its action in

causing the letter of the 19th December 2002 being written evidences the seriousness with which it regarded the dangers of OP

products and fortifies my view that the advice of the Committee which was followed by the Respondent was proportionate.

(2). Whether the decision of the Respondent is ultra vires on the grounds set out in paragraphs 37 and 38 of the Amended

Statement of Grounds.

44. This issue was refined in the course of the hearing. Both the A.C.V.M. and the I.M.B. it is alleged took into account off label use

of product. The Directive 2001/82/EC Article 83.1(a) provides as follows –

“1. The Competent Authorities of the Member States shall suspend or withdraw marketing authorisation when it is clear

that

(a) the veterinary medicinal product proves to be harmful under the conditions of use stated at the time of

application for authorisation or subsequently

45. The Animal Remedies Regulations 1996 Regulation 19 provides as follows –

19. The Competent Authority shall suspend or revoke a veterinary product authorisation where in the opinion of the

Competent Authority –

(1) The animal remedy proves to be harmful under the conditions of use stated at the time of application for

authorisation or subsequently, or where the animal remedy does not have any therapeutic effect or its qualitive or

quantitive composition is not as stated.

46. The Applicant contends that the Respondent took into account off label use of product: specifically the product authorisations of

the Applicant in the Schedule thereto require persons handling or working with the product to take precautions and to wear suitable

protective clothing including gloves and wellington boots. The Report of the Liaison Committee of 21st March 2000 acknowledged that

familiarity among sheep farmers with sheep dipping may have led to complacency in the use of recommended personal protective

equipment and poor dipping practices and that many farmers chose not to wear personal protective equipment during dipping

especially in warm weather as it was uncomfortable. The Applicant’s label specifically warns those using the products to wear

protective clothing. The Applicant argues that having regard to the provisions of the Directive and the Regulations mentioned above it

was inappropriate for the Respondent to take into account the circumstance that the product might be used by persons not wearing

protective clothing. “Off label use” is defined in Article 1.6 of the Directive –

“The use of a veterinary medicinal product that is not in accordance with the summary of the product characteristics

including the misuse and serious abuse of the product.”

47. The term is used in the Directive in Articles dealing with pharmacovigilance rather than in relation to the withdrawal or suspension

of authorisations. The Applicant is correct in its submission that suspension or withdrawal should not be triggered by off label use but

this is not the term used in Article 83 or Regulation 19. Recital (2) to the Directive reads as follows –

“The primary purpose of any rules for the production and distribution of veterinary medicinal products must be the

safeguarding of public health.”

48. Thus Article 83.1 of the Directive provides that if the product proves to be harmful under the conditions of use, which I

understand to be the conditions of use in the Schedule to the Directive as varied by the authorisation the Member State shall

suspend or withdraw the marketing authorisation. Included in Part III of the Schedule at 6.4 are details of the container which refer

to the container formerly used by the Applicant and which I accept was less safe than the container at present in use. However at

the date of the Report of the Liaison Committee there was no generically available closed system and closed systems which were

available continued to expose the operator to contact with the OP product at the point of setting up or dismantling or were defective

in point of the control for the performance needed by an operator or had the potential for misuse. Further the Report of the Liaison

Committee evaluated recent scientific data at paragraph 2 and its evaluation accepts that OP products on the balance of evidence

can be harmful to humans in terms of acute poisoning: further the possibility of OP exposure causing psychiatric illness could not be

excluded. It also noted the position adopted in the Report of the Veterinary Products Committee (UK) on Op Sheep Dips of November

1999 which advised that marketing authorisations be suspended until the design of containers should be improved to minimise the risk

of exposure to OP concentrate. The Liaison Committee inter alia recommended that the containers in which OP concentrates are

supplied for veterinary use be kept under review by the I.M.B. in the light of national and international developments and that all

authorised products should comply with any new standards. The Willis Report prepared on behalf of the Applicant identified risks

associated with the Applicant’s delivery system –

Splashing during pouring - low/medium

Dripping down side of packaging from lid – low/medium

On site damage and leakage – low

On site puncturing and spillage – low

Inhalation – low.

49. It also recognised risks associated with the rival products which use a closed delivery system. However it is clear that risks were

identified even by the Applicant. The evaluation of those risks is a matter for the Respondent: this Court on Judicial Review will not

act as a forum for an appeal and provided there was evidence which if accepted would justify the decision of the Respondent will not

interfere. In the reports which I have mentioned including the Applicant’s own report risks to human health are identified. These risks

exist notwithstanding use of the product under the conditions of use. Therefore the Respondent could in the exercise of its powers

under the 1996 Regulations Article 19 suspend or revoke the Applicant’s product.

(3) Whether the Decision of the Respondent was arrived at in breach of the principle of proportionality in circumstances

where there were no adverse reactions or adverse human reactions to the Applicant’s product.

50. I have dealt with this issue in dealing with Issue 1. There have been no reported adverse human reactions to the Applicant’s

products. However the concerns which exist in relation to OP products is clear: see the COT Report. I am satisfied that the

precautionary principle applies. The response of the Respondent was not disproportionate.

(4) Whether the Respondents impermissibly took into account the economic implications for companies which are the

competitors of the Applicant.

51. It is clear from the documents exhibited herein that the Applicant’s competitors were aggrieved in that they had taken steps to

move to a closed system of delivery presumably at considerable expense while the Applicant had not. The Respondent was aware of

this. However correspondence emanating from the Respondent is informative. In the letter dated 21st November 2002 to the

Applicant it was made clear that the appeal would be based on the safety of the Applicant’s products for human health. This

approach was borne out by the refusal in a letter dated 27th November 2002 by the Respondent to make available to the Applicant

studies related to competitor products. That letter also emphatically states that matters relating to commercial considerations or to

products marketed by other companies are outside the scope of the appeal which was to be based on the safety of the Applicant’s

products for human health only. Again the letter from the Respondent to the Applicant dated 13th December 2002 repeats that the

appeal will focus on the risk of the Applicant’s products for human health and that matters relating to commercial considerations or to

products marketed by other companies would be outside the scope of the appeal. I have also the Affidavit of Dr. Beechner sworn on

the 6th February 2003 where at paragraph 34 he deposes that the A.C.V.M. had no regard to the interests of the Applicant’s

competitors in reaching its decision.

52. On review of all the evidence before me the Applicant has failed to satisfy me that the Respondent had regard to the commercial

considerations of the Applicant’s competitors.

(5)(b) Whether the decisions of the Respondent were vitiated by objective bias by the participation of Mr. P.J. O’Connor,

Chairman of the Advisory Committee for Veterinary Medicines in the decision of the Board on the 26th February 2003.

53. The Applicant’s argument on this issue relies on matters raised in relation to the Second Issue in particular the Applicant again

raises the contention that the Respondent erred in concentrating on an open system having regard to the phrase “closed system” and

not having regard to the phrase “or similar”. However it is abundantly clear that the Applicant’s system is not a closed system and

further it is not similar to a closed system: it is an open system. I find no fault with the Respondent in this regard.

54. Mr. P.J. O’Connor acted as Chairman of the A.C.V.M. but also took part in the meeting of the Board of the Respondent which

made the decision in relation to the Applicant’s products.

55. In the event of a judicial decision made after a hearing inter partes such circumstances would give rise to a finding of objective

bias. The proceedings with which I am concerned however are not inter partes. The true situation is that the Respondent in the first

instance through the A.C.V.M. was exercising an administrative function to which requirements of natural justice applied. For this

reason having formed a preliminary view it permitted the Applicant to make representations to it before reaching a conclusion. The

A.C.V.M. fulfilled its statutory responsibility by furnishing advice to the Respondent. The Respondent considered this advice and made

its decision. Mr. O’Connor in addition to being a member of the A.C.V.M. is also an appointee of the Minister to the Board. He also

enjoys status as an expert. In partaking in the decision of the Board he was fulfilling the responsibility entrusted to him by the

Minister. The position is quite different to that which pertained in the cases relied upon by the Applicant – Radio Limerick One Limited

v Independent Radio and Television Commission (1997) 2 I.R. 291, ODonoghue v Veterinary Council (1975) I.R. 398, O’Neill and Bova

Genetics Limited v Irish Hereford Breeds Society Limited (1992) 1 I.R. 431, 450.

56. In the first of these cases the decision making body was composed in part of persons engaged in the media and who might have

had a pecuniary or proprietary interest in the subject matter of the proceedings: it is not suggested that Mr. O’Connor had such an

interest. Then the dicta of Keane J. at page 316 of the Report are relevant –

“In the present case, the statutory provisions already referred to clearly envisaged that the membership of the

Commission may consist, in part at least, of persons engaged in the media who may be assumed to have a special

knowledge of the matters with which the Commission has to deal. The fact that its membership is so composed may mean

that, in specific instances, when it comes to deal with matters as crucial as the entering into a contract or a suspension

or termination, its decisions, although undoubtedly quasi judicial in nature in necessitating the observance of natural

justice and fair procedures, may also not have the appearance of impartiality which would be required of a Court of

Justice. That, of itself, would not vitiate its conclusions, provided it reached them in good faith and having given the

persons affected the protection of natural justice and fair procedures.”

57. In the second case a member of the Veterinary Council had been the complainant at an enquiry held before a special Committee

of Enquiry and also sat on the Council at its meeting to consider the Report of that Committee: this was held to infringe the nemo

judex rule. I do not see that the decision in this case is relevant to the circumstances with which I am dealing: circumstances in the

present instance are akin to those in the Radio Limerick One Limited case.

58. Finally in O’Neill v Irish Hereford Breeds Society Limited Murphy J. held that not every prior involvement by a member of a board

exercising a quasi judicial function with a person or the conduct of a person whose affairs were under consideration by the body

would necessarily disbar the member from acting in the matter. Certain forms of involvement would have that result. In that case the

Chairman and members of the Editing Committee of the Defendant had recommended the expulsion of the First Named Plaintiff and

attended the meeting of the Council of the Defendant which decided to expel the Plaintiff and took a full part in the meeting. The

proceedings there were essentially inter partes which I am satisfied is not the case here. There is to my mind a significant difference

between a complainant on the one hand and an expert statutorily authorised to advise. I am satisfied that the circumstances in this

case are such that involvement in an earlier stage in the administrative process in issue would not disqualify from partaking in the

ultimate decision.

(7) Whether the decision of the Respondent is vitiated by manifest error or misuse of power as identified in paragraph 51 of

the Amended Statement of Grounds and whether the decision of the Respondent is vitiated by a distortion or manifest error

of assessment of facts or misuse of power or a clear breach of the bounds of its discretion as a consequence of (i) the non

disclosure of the Raporteur’s Report or paragraph (ii) omission to refer to “or similar aimed at reducing operator exposure

to the concentrate.

59. I have already dealt with the argument in relation to the failure to concentrate on the phrase “or similar” after the phrase “closed

system”. For this argument to carry any weight it would be necessary that the Applicant’s system be similar to a closed system and I

am satisfied that it is not.

60. Apart from the foregoing the Applicant relies upon the Judgment of the Supreme Court in SIAC Construction Limited v Mayo

County Council 2002 3 I.R. 148 as imposing upon the Court a duty to examine the accuracy of the findings of fact and law made by

the Respondent and to verify that the decision of the Respondent is not vitiated by a manifest error or a misuse of power and that it

did not clearly exceed the bounds of its discretion. In the course of its judgment the Supreme Court referred to the decision of the

European Court of Justice in Upjohn Limited v Licensing Authority (1999) 1 WLR 927 and again in Matra S.A. v Commissioner of the

European Communities (1993) ECR 1 – 3203. While I accept this line of authority I do not see that it avails the Applicant anything

here. In R v Licensing Authority Ex Parte Novartis Pharmacuticals U.K. Limited Queens Bench 30th March 2000 in dealing with both

the Upjohn and Matra cases said –

“Mr. Sales went on to argue, and again I accept, that it followed that it was inappropriate in an application for Judicial

Review to invite the Court to engage in a debate between experts on matters of scientific opinion, referring particularly to

paragraphs 16 and 35 of the Applicant’s skeleton argument on the question of whether the various products had a

different pharmaceutical form. The Court should respect the judgment of the decision maker unless it had no rational basis

which the skeleton argument did not begin to demonstrate here.”

61. Again in R v Medicines Control Agency Ex Parte Pharma Nord (UK) 1998 CMLR 109 at 121 Lord Woolf M.R. at page 122 said –

“Both the determination of the facts and the application of the policy in a case such as this is not ideally suited to the

adversarial processes of the Courts. If the case was one where the M.C.A. could not reasonably have come to the

decision which it did so that the outcome was one which is conventionally determined on application for Judicial Review,

the position would be different. However in this case the M.C.A. is in a better position to evaluate the evidence than a

Judge. It has accumulated experience in relation to other products which a Court lacks. It is an expert body. The M.C.A.

has to develop a consistent policy between similar products. The issues are to use Simon Brown L.J’s approach ones in

relation to which the Court should be wary of becoming involved.”

62. In the present case even applying the heightened standards suggested by the Applicant I have been unable to find a manifest

error or a misuse of power on the part of the Respondent or that the Respondent exceeded the bounds of its discretion. In particular I

find no objection to the toilet test as described carried out by Dr. Beechner particularly when it is compared to the desktop study

(the Willis Report) relied upon by the Applicant. The evidence has not satisfied me that the risk analysis carried out was unscientific.

The consideration of “similar” systems of delivery to closed systems is irrelevant as on any assessment of the facts the Applicant’s

system is not similar to a closed system identified for me.

63. I refuse the Applicant the relief which it seeks. In these circumstances I propose hearing Counsel as to the Order which I should

make and in particular whether I should order the withdrawal of the Applicant’s products and if so the timescale for the same.